RATIO-SALBUTAMOL SOLUTION

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

SALBUTAMOL (SALBUTAMOL SULFATE)

Verfügbar ab:

TEVA CANADA LIMITED

ATC-Code:

R03AC02

INN (Internationale Bezeichnung):

SALBUTAMOL

Dosierung:

1MG

Darreichungsform:

SOLUTION

Zusammensetzung:

SALBUTAMOL (SALBUTAMOL SULFATE) 1MG

Verabreichungsweg:

INHALATION

Einheiten im Paket:

10ML

Verschreibungstyp:

Prescription

Therapiebereich:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0108887007; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2018-05-18

Fachinformation

PRODUCT MONOGRAPH
RATIO-SALBUTAMOL
salbutamol sulphate respirator solution
1 mg/mL
Bronchodilator
(beta
2
-adrenergic stimulant)
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
Control: 166142
DATE OF PREPARATION:
JULY 24, 2013
2/32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................................
3
ADVERSE REACTIONS
........................................................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................................................
8
DOSAGE AND ADMINISTRATION
....................................................................................................................
10
OVERDOSAGE
.....................................................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
...................................................................................................
12
STORAGE AND STABILITY
...............................................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................................
14
PART II: S